Aktuellt
SENASTE
I-Tech recently published that the BPC committee has adopted the previous interpretation of the endocrine disruption framework, meaning that I-Techs’s substance medetomidine, is considered to have endocrine-disruptive properties. The news is in line with our expectations and I-Tech will now continue to defend medetomidine in the next instance, which includes a socioeconomic analysis.
LÄS MER
